Dolby Laboratories Financial Statements (DLB)
|
|
|
|
Report date
|
|
|
17.11.2023 |
02.02.2024 |
02.05.2024 |
07.08.2024 |
19.11.2024 |
|
19.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
290.6 |
315.6 |
364.5 |
288.8 |
304.8 |
|
1 274 |
|
Operating Income, bln rub |
|
|
-3.49 |
66.2 |
109.0 |
36.8 |
45.1 |
|
257.0 |
|
EBITDA, bln rub |
? |
|
82.0 |
93.3 |
127.3 |
62.1 |
59.7 |
|
342.3 |
|
Net profit, bln rub |
? |
|
9.19 |
67.0 |
97.8 |
38.4 |
58.6 |
|
261.8 |
|
|
OCF, bln rub |
? |
|
85.0 |
8.41 |
181.4 |
21.3 |
116.2 |
|
327.3 |
|
CAPEX, bln rub |
? |
|
8.19 |
6.10 |
8.92 |
7.61 |
7.38 |
|
30.0 |
|
FCF, bln rub |
? |
|
76.8 |
2.31 |
172.5 |
13.7 |
108.8 |
|
297.2 |
|
Dividend payout, bln rub
|
|
|
25.8 |
28.6 |
28.7 |
28.7 |
28.6 |
|
114.6 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
281.1% |
42.6% |
29.4% |
74.7% |
48.8% |
|
43.8% |
|
|
OPEX, bln rub |
|
|
227.9 |
217.3 |
216.8 |
216.4 |
225.7 |
|
876.2 |
|
Cost of production, bln rub |
|
|
35.6 |
32.1 |
38.8 |
35.7 |
34.0 |
|
140.5 |
|
R&D, bln rub |
|
|
70.4 |
67.0 |
62.5 |
65.5 |
68.6 |
|
263.7 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
2 980 |
2 936 |
3 045 |
2 974 |
3 110 |
|
3 110 |
|
Net Assets, bln rub |
? |
|
2 355 |
2 346 |
2 421 |
2 433 |
2 477 |
|
2 477 |
|
Debt, bln rub |
|
|
50.6 |
47.2 |
51.9 |
48.2 |
47.0 |
|
47.0 |
|
Cash, bln rub |
|
|
884.5 |
797.6 |
825.4 |
869.0 |
577.8 |
|
577.8 |
|
Net debt, bln rub |
|
|
-833.9 |
-750.4 |
-773.5 |
-820.8 |
-530.8 |
|
-530.8 |
|
|
Ordinary share price, rub |
|
|
79.3 |
86.2 |
83.8 |
79.2 |
75.6 |
|
83.5 |
|
Number of ordinary shares, mln |
|
|
95.7 |
95.4 |
95.7 |
95.7 |
95.4 |
|
95.4 |
|
|
Market cap, bln rub |
|
|
7 585 |
8 220 |
8 018 |
7 581 |
7 213 |
|
7 961 |
|
EV, bln rub |
? |
|
6 751 |
7 469 |
7 245 |
6 760 |
6 682 |
|
7 430 |
|
Book value, bln rub |
|
|
1 779 |
1 776 |
1 860 |
1 880 |
1 509 |
|
1 509 |
|
|
EPS, rub |
? |
|
0.10 |
0.70 |
1.02 |
0.40 |
0.61 |
|
2.74 |
|
FCF/share, rub |
|
|
0.80 |
0.02 |
1.80 |
0.14 |
1.14 |
|
3.12 |
|
BV/share, rub |
|
|
18.6 |
18.6 |
19.4 |
19.6 |
15.8 |
|
15.8 |
|
|
EBITDA margin, % |
? |
|
28.2% |
29.6% |
34.9% |
21.5% |
19.6% |
|
26.9% |
|
Net margin, % |
? |
|
3.16% |
21.2% |
26.8% |
13.3% |
19.2% |
|
20.6% |
|
FCF yield, % |
? |
|
5.09% |
3.53% |
4.56% |
3.50% |
4.12% |
|
3.73% |
|
ROE, % |
? |
|
11.9% |
8.03% |
7.86% |
8.73% |
10.6% |
|
10.6% |
|
ROA, % |
? |
|
9.40% |
6.41% |
6.25% |
7.14% |
8.42% |
|
8.42% |
|
|
P/E |
? |
|
27.1 |
43.7 |
42.1 |
35.7 |
27.5 |
|
30.4 |
|
P/FCF |
|
|
19.7 |
28.4 |
21.9 |
28.6 |
24.3 |
|
26.8 |
|
P/S |
? |
|
4.64 |
6.42 |
6.32 |
6.02 |
5.66 |
|
6.25 |
|
P/BV |
? |
|
4.26 |
4.63 |
4.31 |
4.03 |
4.78 |
|
5.27 |
|
EV/EBITDA |
? |
|
13.5 |
21.4 |
19.7 |
18.5 |
19.5 |
|
21.7 |
|
Debt/EBITDA |
|
|
-1.67 |
-2.15 |
-2.11 |
-2.25 |
-1.55 |
|
-1.55 |
|
|
R&D/CAPEX, % |
|
|
860.4% |
1 099% |
700.9% |
860.4% |
930.2% |
|
878.7% |
|
|
CAPEX/Revenue, % |
|
|
2.82% |
1.93% |
2.45% |
2.64% |
2.42% |
|
2.36% |
|
| Dolby Laboratories shareholders |
